Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 11/20 | 0.45 |
| ▸ | BTK | Q06187 | 6/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129806 | 0.93 | TBK1 (0.45) | TBK1IKBKEBTKMAP4K1GSK3B | |
| SCHEMBL18129472 | 0.90 | CHEK1 (0.46) | TBK1IKBKEBTKMAP4K1GSK3B | |
| SCHEMBL18129662 | 0.90 | TBK1 (0.42) | TBK1IKBKEBTKMAP4K1GSK3B | |
| SCHEMBL18129663 | 0.89 | GABRP (0.44) | TBK1IKBKEBTKMAP4K1 | |
| SCHEMBL18129599 | 0.89 | TBK1 (0.42) | TBK1IKBKEBTKMAP4K1 | |
| SCHEMBL18129502 | 0.89 | CHEK1 (0.43) | TBK1IKBKEBTKMAP4K1GSK3B | |
| SCHEMBL18129569 | 0.88 | TBK1 (0.42) | TBK1IKBKEBTKMAP4K1GSK3B | |
| SCHEMBL18129699 | 0.88 | MAP4K1 (0.46) | TBK1IKBKEMAP4K1 | |
| SCHEMBL18129596 | 0.88 | MAP4K1 (0.46) | TBK1IKBKEMAP4K1 | |
| SCHEMBL18129487 | 0.88 | CHEK1 (0.44) | TBK1IKBKEBTKMAP4K1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | claimed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | claimed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TANK, NFKBIA, TBK1 | TBK1 3/4885IKBKE 6/4885BTK 100/4885 |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | NFKBIA, TANK, TBK1 | TBK1 3/4885IKBKE 6/4885BTK 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.